Artículos de revistas sobre el tema "CDK17"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "CDK17".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Liu, Mingfa, Zhennan Xu, Zepeng Du, Bingli Wu, Tao Jin, Ke Xu, Liyan Xu, Enmin Li y Haixiong Xu. "The Identification of Key Genes and Pathways in Glioma by Bioinformatics Analysis". Journal of Immunology Research 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/1278081.
Texto completoLiang, Kaiwei, Xin Gao, Joshua M. Gilmore, Laurence Florens, Michael P. Washburn, Edwin Smith y Ali Shilatifard. "Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing". Molecular and Cellular Biology 35, n.º 6 (5 de enero de 2015): 928–38. http://dx.doi.org/10.1128/mcb.01426-14.
Texto completoLier, S., I. Rein, S. Lund, A. Lång, E. Lång, N. Meyer, A. Dutta et al. "P10.12.A CDK12/CDK13 inhibition disrupts a transcriptional program critical for glioblastoma survival". Neuro-Oncology 24, Supplement_2 (1 de septiembre de 2022): ii51. http://dx.doi.org/10.1093/neuonc/noac174.177.
Texto completoKohoutek, Jiri y Dalibor Blazek. "Cyclin K goes with Cdk12 and Cdk13". Cell Division 7, n.º 1 (2012): 12. http://dx.doi.org/10.1186/1747-1028-7-12.
Texto completoFan, Zheng, Jennifer R. Devlin, Simon J. Hogg, Maria A. Doyle, Paul F. Harrison, Izabela Todorovski, Leonie A. Cluse et al. "CDK13 cooperates with CDK12 to control global RNA polymerase II processivity". Science Advances 6, n.º 18 (29 de abril de 2020): eaaz5041. http://dx.doi.org/10.1126/sciadv.aaz5041.
Texto completoShah, Muzna, Muhammad Fazal Hussain Qureshi, Danish Mohammad, Mahira Lakhani, Tabinda Urooj y Shamim Mushtaq. "CDKs family -a glimpse into the past and present: from cell cycle control to current biological functions". Asian Pacific Journal of Cancer Biology 5, n.º 1 (25 de febrero de 2020): 1–9. http://dx.doi.org/10.31557/apjcb.2020.5.1.1-9.
Texto completoZhang, Bo, Xuelin Zhong, Moira Sauane, Yihong Zhao y Zhi-Liang Zheng. "Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy". Cells 9, n.º 3 (4 de marzo de 2020): 621. http://dx.doi.org/10.3390/cells9030621.
Texto completoGuiro, Joana, Mathias Fagbemi, Michael Tellier, Justyna Zaborowska, Stephanie Barker, Marjorie Fournier y Shona Murphy. "CAPTURE of the Human U2 snRNA Genes Expands the Repertoire of Associated Factors". Biomolecules 12, n.º 5 (14 de mayo de 2022): 704. http://dx.doi.org/10.3390/biom12050704.
Texto completoQuereda, Victor, Simon Bayle, Francesca Vena, Sylvia M. Frydman, Andrii Monastyrskyi, William R. Roush y Derek R. Duckett. "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer". Cancer Cell 36, n.º 5 (noviembre de 2019): 545–58. http://dx.doi.org/10.1016/j.ccell.2019.09.004.
Texto completoZhang, Tinghu, Nicholas Kwiatkowski, Calla M. Olson, Sarah E. Dixon-Clarke, Brian J. Abraham, Ann K. Greifenberg, Scott B. Ficarro et al. "Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors". Nature Chemical Biology 12, n.º 10 (29 de agosto de 2016): 876–84. http://dx.doi.org/10.1038/nchembio.2166.
Texto completoGreenleaf, Arno L. "Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium". Transcription 10, n.º 2 (22 de octubre de 2018): 91–110. http://dx.doi.org/10.1080/21541264.2018.1535211.
Texto completoVaradarajan, Ramya, Joseph Ayeni, Zhigang Jin, Ellen Homola y Shelagh D. Campbell. "Myt1 inhibition of Cyclin A/Cdk1 is essential for fusome integrity and premeiotic centriole engagement in Drosophila spermatocytes". Molecular Biology of the Cell 27, n.º 13 (julio de 2016): 2051–63. http://dx.doi.org/10.1091/mbc.e16-02-0104.
Texto completoPraditsuktavorn, Pannee, Benet Pera, Nicholas Kwiatkowski, ShaoNing Yang, Tinghu Zhang, Nathanael Gray y Leandro Cerchietti. "Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors". Blood 124, n.º 21 (6 de diciembre de 2014): 810. http://dx.doi.org/10.1182/blood.v124.21.810.810.
Texto completoChen, Hong-Ru, Guan-Ting Lin, Chun-Kai Huang y Ming-Ji Fann. "Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression". Experimental Neurology 261 (noviembre de 2014): 10–21. http://dx.doi.org/10.1016/j.expneurol.2014.06.024.
Texto completoKapasi, Anokhi J. y Deborah H. Spector. "Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome". Journal of Virology 82, n.º 1 (17 de octubre de 2007): 394–407. http://dx.doi.org/10.1128/jvi.01681-07.
Texto completohu, Shan, David Moebius, Wojciech Dworakowski, Elliott Cooper, Derek LaPlaca, Sydney Alnemy, Phone Perera et al. "Abstract 5393: An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 5393. http://dx.doi.org/10.1158/1538-7445.am2022-5393.
Texto completoKolloch, Lina, Teresa Kreinest, Michael Meisterernst y Andrea Oeckinghaus. "Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells". International Journal of Molecular Sciences 23, n.º 2 (12 de enero de 2022): 812. http://dx.doi.org/10.3390/ijms23020812.
Texto completoStern, Yaakov E., Pompom Ghosh, Hannah L. Walker-Mimms, John W. Mosior, Denis Imbody, Hitendra S. Solanki, Andrii Monastyrskyi, Derek R. Duckett y Eric B. Haura. "Abstract B028: CDK12/13 inhibition antagonizes resistance to KRASG12C inhibitors". Cancer Research 82, n.º 23_Supplement_2 (1 de diciembre de 2022): B028. http://dx.doi.org/10.1158/1538-7445.cancepi22-b028.
Texto completoOgi, Sayaka, Yasuhiro Aga, Kazuhiro Onuma, Hidetoshi Sunamoto, Takashi Matsushita, Ayumi Ogawa, Tohru Hasegawa et al. "Preclinical in vitro and in vivo evaluation of antitumor activity of UD-017, a novel selective and orally available CDK7 inhibitor, in colorectal cancer." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e14085-e14085. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14085.
Texto completoDu, Jianhai, Na Wei, Tongju Guan, Hao Xu, Jianzhong An, Kirkwood A. Pritchard y Yang Shi. "Inhibition of CDKS by roscovitine suppressed LPS-induced ·NO production through inhibiting NFκB activation and BH4 biosynthesis in macrophages". American Journal of Physiology-Cell Physiology 297, n.º 3 (septiembre de 2009): C742—C749. http://dx.doi.org/10.1152/ajpcell.00138.2009.
Texto completoYamakawa, Hiroko, Akio Mizutani, Yasuyoshi Arikawa, Shunsuke Ebara, Yoshihiko Satoh y Daisuke Morishita. "Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 5485. http://dx.doi.org/10.1158/1538-7445.am2022-5485.
Texto completoYao, Yao, Woojun D. Park, Eugenio Morelli, Mehmet Kemal Samur, Nicholas P. Kwiatkowski, Yan Xu, Chandraditya Chakraborty et al. "Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition". Blood 136, Supplement 1 (5 de noviembre de 2020): 1–2. http://dx.doi.org/10.1182/blood-2020-142592.
Texto completoLi, Ji, Porter, Broude, Roninson y Chen. "Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay". Cells 8, n.º 10 (6 de octubre de 2019): 1208. http://dx.doi.org/10.3390/cells8101208.
Texto completoJohannessen, Liv, Nan Ke, Priyanka Sawant, Wojciech Dworakowski, Anthony D'Ippolito, Shanhu Hu, Nisha Rajagopal, Matthew Eaton y Graeme Hodgson. "Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 3585. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3585.
Texto completoLi, Tao-Sheng, Kimikazu Hamano, Masahiko Nishida, Masanori Hayashi, Hiroshi Ito, Akihito Mikamo y Masunori Matsuzaki. "CD117+ stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation". American Journal of Physiology-Heart and Circulatory Physiology 285, n.º 3 (septiembre de 2003): H931—H937. http://dx.doi.org/10.1152/ajpheart.01146.2002.
Texto completoTaylor, Mary Love, Hiba I. Dada, Hannah Florian, Paul Kelly Marcom, Carey K. Anders, Leylah Drusbosky y Jeremy Meyer Force. "Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 1028. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1028.
Texto completoPark, Shin Young, Ki Yun Kim, Do Youn Jun, Su-Kyeong Hwang y Young Ho Kim. "G1 Cell Cycle Arrest and Extrinsic Apoptotic Mechanisms Underlying the Anti-Leukemic Activity of CDK7 Inhibitor BS-181". Cancers 12, n.º 12 (19 de diciembre de 2020): 3845. http://dx.doi.org/10.3390/cancers12123845.
Texto completoHupe, Marie C., Anne Offermann, Finn Becker, Vincent Joerg, Wenzel Vogel, Johannes Braegelmann, Sven Perner y Axel Stuart Merseburger. "Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer." Journal of Clinical Oncology 37, n.º 7_suppl (1 de marzo de 2019): 152. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.152.
Texto completoGramatzki, D., T. Weiss, L. Hänsch, M. Silginer, E. J. Rushing, P. Roth, M. Gramatzki, M. Peipp y M. Weller. "P10.19.B An immunotoxin targeting CD317 for the treatment of glioblastoma". Neuro-Oncology 24, Supplement_2 (1 de septiembre de 2022): ii53. http://dx.doi.org/10.1093/neuonc/noac174.184.
Texto completoTsoi, Helen, Kwong-Fai Wong, John M. Luk y Don Staunton. "Clinical utility of CDH17 biomarker in tumor tissues and liquid biopsies for detection and prognostic staging of colorectal cancer (CRC)." Journal of Global Oncology 5, suppl (7 de octubre de 2019): 53. http://dx.doi.org/10.1200/jgo.2019.5.suppl.53.
Texto completoCain, Chris. "Selecting CDK7". Science-Business eXchange 7, n.º 28 (julio de 2014): 817. http://dx.doi.org/10.1038/scibx.2014.817.
Texto completoZhang, Guizhong, Jian Cheng, Zhao Liu, Tian Deng, Funmilayo Oladunni Adeshakin y Xiaochun Wan. "CD317-mediated cell cytoskeleton regulation as a novel means of tumor immune evasion". Journal of Immunology 204, n.º 1_Supplement (1 de mayo de 2020): 242.43. http://dx.doi.org/10.4049/jimmunol.204.supp.242.43.
Texto completoPeng, Fang, Chuansheng Yang, Yanan Kong, Xiaojia Huang, Yanyu Chen, Yangfan Zhou, Xinhua Xie y Peng Liu. "CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling". Current Cancer Drug Targets 20, n.º 2 (11 de febrero de 2020): 156–65. http://dx.doi.org/10.2174/1568009619666191118113220.
Texto completoLarochelle, Stéphane, Karl A. Merrick, Marie-Emilie Terret, Lara Wohlbold, Nora M. Barboza, Chao Zhang, Kevan M. Shokat, Prasad V. Jallepalli y Robert P. Fisher. "Requirements for Cdk7 in the Assembly of Cdk1/Cyclin B and Activation of Cdk2 Revealed by Chemical Genetics in Human Cells". Molecular Cell 25, n.º 6 (marzo de 2007): 839–50. http://dx.doi.org/10.1016/j.molcel.2007.02.003.
Texto completoHänsch, L., M. Peipp, R. Myburgh, M. Silginer, T. Weiss, D. Gramatzki, F. Vasella, M. Manz, M. Weller y P. Roth. "PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma". Neuro-Oncology 23, Supplement_2 (1 de septiembre de 2021): ii2. http://dx.doi.org/10.1093/neuonc/noab180.005.
Texto completoTun, Nay Min y Gina M. Villani. "Predictive value of KIT immunohistochemical staining for KIT mutations in patients with gastrointestinal stromal tumors (GIST): A systematic review." Journal of Clinical Oncology 30, n.º 4_suppl (1 de febrero de 2012): 30. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.30.
Texto completoYang, Bikang, Jing Chen y Yincheng Teng. "CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration". Journal of Immunology Research 2021 (11 de febrero de 2021): 1–14. http://dx.doi.org/10.1155/2021/6645885.
Texto completoYang, L. L., L. Wu, G. T. Yu, W. F. Zhang, B. Liu y Z. J. Sun. "CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis". Journal of Dental Research 97, n.º 7 (27 de febrero de 2018): 787–94. http://dx.doi.org/10.1177/0022034518758604.
Texto completoGramatzki, Dorothee, Emese Szabo, Martin Gramatzki, Matthias Peipp y Michael Weller. "Targeting of CD317 by the immunotoxin HM1.24-ETA’ to allow immunotherapy in glioblastoma patients." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e13560-e13560. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e13560.
Texto completoLi, Juan, Shaokai Luo, Guocai Zhang, Wende Hong y Xiuzhen Tong. "Expression of the CD117 Antigen on Multiple Myeloma and Its Significance." Blood 104, n.º 11 (16 de noviembre de 2004): 4867. http://dx.doi.org/10.1182/blood.v104.11.4867.4867.
Texto completoZhou, Jun, Xiaoqun Yang, Luting Zhou, Peipei Zhang y Chaofu Wang. "Combined Immunohistochemistry for the “Three 7” Markers (CK7, CD117, and Claudin-7) Is Useful in the Diagnosis of Chromophobe Renal Cell Carcinoma and for the Exclusion of Mimics: Diagnostic Experience from a Single Institution". Disease Markers 2019 (13 de octubre de 2019): 1–9. http://dx.doi.org/10.1155/2019/4708154.
Texto completoGoh, Kee C., Wai C. Ong, Changyong Hu, Ai L. Liang, Walter Stunkel, Yong C. Tan, Kanda Sangthongpitag et al. "SB1317, a Potent and Orally Active FLT3-CDK Inhibitor with High Anti-Tumor Efficacy in Models of Hematological Malignancies." Blood 110, n.º 11 (16 de noviembre de 2007): 1593. http://dx.doi.org/10.1182/blood.v110.11.1593.1593.
Texto completoChalfant, Victor, Carlos Riveros, Sanjeev Shukla, Teruko Osumi y K. Balaji. "Abstract 1622: Signaling of cyclin-dependent kinase 12 (CDK12) in prostate cancer cell lines". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1622. http://dx.doi.org/10.1158/1538-7445.am2022-1622.
Texto completoFujiwara, Kentaro, Atsushi B. Tsuji, Hitomi Sudo, Aya Sugyo, Hiroki Akiba, Hiroko Iwanari, Osamu Kusano-Arai et al. "111In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis". Annals of Nuclear Medicine 34, n.º 1 (12 de octubre de 2019): 13–23. http://dx.doi.org/10.1007/s12149-019-01408-y.
Texto completoAhmed, Rehana L., Daniel P. Shaughnessy, Todd P. Knutson, Rachel I. Vogel, Khalil Ahmed, Betsy T. Kren y Janeen H. Trembley. "CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells". Pharmaceuticals 12, n.º 2 (2 de abril de 2019): 50. http://dx.doi.org/10.3390/ph12020050.
Texto completoWang, Dong, Bethany Veo, Angela Pierce, Sujatha Venkataraman y Rajeev Vibhakar. "MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma". Neuro-Oncology 24, Supplement_1 (1 de junio de 2022): i125. http://dx.doi.org/10.1093/neuonc/noac079.455.
Texto completoВалова, Я. В., Э. Ф. Муллагалеева, Э. Т. Мингажева, Д. С. Прокофьева, А. Х. Нургалиева, Р. Р. Фаисханова y Э. К. Хуснутдинова. "Screening for a variant of the splicing site in the CDK12 gene in patients with ovarian cancer". Nauchno-prakticheskii zhurnal «Medicinskaia genetika», n.º 6(215) (29 de junio de 2020): 42–43. http://dx.doi.org/10.25557/2073-7998.2020.06.42-43.
Texto completoHupe, Marie C., Anne Offermann, Cleopatra Schreiber, Axel Stuart Merseburger y Sven Perner. "CDK12 upregulation and adverse correlation with tumor-associated immune cell infiltrates in prostate cancer." Journal of Clinical Oncology 38, n.º 6_suppl (20 de febrero de 2020): 181. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.181.
Texto completoAlfaleh, Mohamed, Neetika Arora, Michael Yeh, Christopher de Bakker, Christopher Howard, Philip Macpherson, Rachel Allavena et al. "Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning". Antibodies 8, n.º 1 (12 de febrero de 2019): 15. http://dx.doi.org/10.3390/antib8010015.
Texto completoLudwig, Marion, Anita Tölk, Anna Skorska, Christian Maschmeier, Ralf Gaebel, Cornelia Aquilina Lux, Gustav Steinhoff y Robert David. "Exploiting AT2R to Improve CD117 Stem Cell Function In Vitro and In Vivo - Perspectives for Cardiac Stem Cell Therapy". Cellular Physiology and Biochemistry 37, n.º 1 (2015): 77–93. http://dx.doi.org/10.1159/000430335.
Texto completo